Adlai Nortye Announces Oral Presentation for AN4035 Program Update at ENA Symposium

Adlai Nortye Group shares are trading higher after the company announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany for the anti-EGFR antibody cetuximab.

Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday

U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.

Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody

These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid

Jefferies Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $31

Jefferies analyst Maury Raycroft initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Buy rating and announces Price Target of $31.

HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target